TY - JOUR
T1 - Trends in infective endocarditis in California and New York state, 1998-2013
AU - Toyoda, Nana
AU - Chikwe, Joanna
AU - Itagaki, Shinobu
AU - Gelijns, Annetine C.
AU - Adams, David H.
AU - Egorova, Natalia N.
N1 - Publisher Copyright:
© 2017 American Medical Association.
PY - 2017/4/25
Y1 - 2017/4/25
N2 - IMPORTANCE Prophylaxis and treatment guidelines for infective endocarditis have changed substantially over the past decade. In the United States, few population-based studies have explored the contemporary epidemiology and outcomes of endocarditis. OBJECTIVE To quantify trends in the incidence and etiologies of infective endocarditis in the United States. DESIGN, SETTING, AND PARTICIPANTS Retrospective population epidemiology study of patients hospitalized with a first episode of endocarditis identified from mandatory state databases in California and New York State between January 1, 1998, and December 31, 2013. EXPOSURE Infective endocarditis. MAIN OUTCOMES AND MEASURES Outcomeswere crude and standardized incidence of endocarditis and trends in patient characteristics and disease etiology. Trends in acquisition mode, organism, and mortality were analyzed. RESULTS Among 75 829 patients with first episodes of endocarditis (mean [SD] age, 62.3 [18.9] years; 59.1%male), the standardized annual incidence was stable between 7.6 (95%CI, 7.4 to 7.9) and 7.8 (95%CI, 7.6 to 8.0) cases per 100 000 persons (annual percentage change [APC],-0.06%; 95%CI,-0.3%to 0.2%; P = .59). From 1998 through 2013, the proportion of patients with native-valve endocarditis decreased (from 74.5% to 68.4%; APC,-0.7%; 95%CI,-0.9%to-0.5%; P < .001). Prosthetic-valve endocarditis increased (from 12.0% to 13.8%; APC, 1.3%; 95%CI, 0.8% to 1.7%; P < .001), and cardiac device-related endocarditis increased (from 1.3%to 4.1%; APC, 8.8%; 95%CI, 7.8% to 9.9%; P < .001). The proportion of patients with health care-associated nosocomial endocarditis decreased (from 17.7%to 15.3%; APC,-1.0%; 95%CI,-1.4%to-0.7%; P < .001). The proportion of patients with health care-associated nonnosocomial endocarditis increased (from 32.1%to 35.9%; APC, 0.8%; 95%CI, 0.5%to 1.1%; P < .001). The incidence of oral streptococcal endocarditis did not increase (unadjusted: APC,-0.1%; 95%CI,-0.8% to 0.6%; P = .77; adjusted: APC,-1.3%; 95%CI,-1.8%to-0.7%; P < .001). Crude 90-day mortality was unchanged (from 23.9%to 24.2%; APC,-0.3%; 95%CI,-1.0%to 0.4%; P = .44); adjusted risk of 90-day mortality decreased (adjusted hazard ratio per year, 0.982; 95%CI, 0.978 to 0.986; P < .001). CONCLUSIONS AND RELEVANCE In California and New York State, the overall standardized incidence of infective endocarditis was stable from 1998 through 2013, with changes in patient characteristics and etiology over this time.
AB - IMPORTANCE Prophylaxis and treatment guidelines for infective endocarditis have changed substantially over the past decade. In the United States, few population-based studies have explored the contemporary epidemiology and outcomes of endocarditis. OBJECTIVE To quantify trends in the incidence and etiologies of infective endocarditis in the United States. DESIGN, SETTING, AND PARTICIPANTS Retrospective population epidemiology study of patients hospitalized with a first episode of endocarditis identified from mandatory state databases in California and New York State between January 1, 1998, and December 31, 2013. EXPOSURE Infective endocarditis. MAIN OUTCOMES AND MEASURES Outcomeswere crude and standardized incidence of endocarditis and trends in patient characteristics and disease etiology. Trends in acquisition mode, organism, and mortality were analyzed. RESULTS Among 75 829 patients with first episodes of endocarditis (mean [SD] age, 62.3 [18.9] years; 59.1%male), the standardized annual incidence was stable between 7.6 (95%CI, 7.4 to 7.9) and 7.8 (95%CI, 7.6 to 8.0) cases per 100 000 persons (annual percentage change [APC],-0.06%; 95%CI,-0.3%to 0.2%; P = .59). From 1998 through 2013, the proportion of patients with native-valve endocarditis decreased (from 74.5% to 68.4%; APC,-0.7%; 95%CI,-0.9%to-0.5%; P < .001). Prosthetic-valve endocarditis increased (from 12.0% to 13.8%; APC, 1.3%; 95%CI, 0.8% to 1.7%; P < .001), and cardiac device-related endocarditis increased (from 1.3%to 4.1%; APC, 8.8%; 95%CI, 7.8% to 9.9%; P < .001). The proportion of patients with health care-associated nosocomial endocarditis decreased (from 17.7%to 15.3%; APC,-1.0%; 95%CI,-1.4%to-0.7%; P < .001). The proportion of patients with health care-associated nonnosocomial endocarditis increased (from 32.1%to 35.9%; APC, 0.8%; 95%CI, 0.5%to 1.1%; P < .001). The incidence of oral streptococcal endocarditis did not increase (unadjusted: APC,-0.1%; 95%CI,-0.8% to 0.6%; P = .77; adjusted: APC,-1.3%; 95%CI,-1.8%to-0.7%; P < .001). Crude 90-day mortality was unchanged (from 23.9%to 24.2%; APC,-0.3%; 95%CI,-1.0%to 0.4%; P = .44); adjusted risk of 90-day mortality decreased (adjusted hazard ratio per year, 0.982; 95%CI, 0.978 to 0.986; P < .001). CONCLUSIONS AND RELEVANCE In California and New York State, the overall standardized incidence of infective endocarditis was stable from 1998 through 2013, with changes in patient characteristics and etiology over this time.
UR - http://www.scopus.com/inward/record.url?scp=85018304430&partnerID=8YFLogxK
U2 - 10.1001/jama.2017.4287
DO - 10.1001/jama.2017.4287
M3 - Article
C2 - 28444279
AN - SCOPUS:85018304430
SN - 0098-7484
VL - 317
SP - 1652
EP - 1660
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 16
ER -